Shares of Novavax Inc. NVAX slid 6.10% to $8.46 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.09% to 19,281.40 ...

Biotech firm Novavax dropped after cutting its annual revenue forecast due to lower-than-expected sales of its COVID-19 ...

This article summarizes key developments in the health sector including a lawsuit blocking UnitedHealth's purchase of ...

Yes, you can get your flu and COVID-19 shots at the same time. Don't call them boosters — they're not just another dose of ...

Novavax's (NVAX) stock was trading down more than 6% Tuesday afternoon after the company lowered its guidance for sales for ...

FY24 consensus $761.46M. Cuts FY24 product sales view to $175M-$225M from $275M-$375M. Raises FY24 Licensing, Royalties and Other Revenue view ...

The FDA has lifted its clinical hold on Novavax's combined COVID-19 and influenza vaccine trial, finding no link between the ...

Novavax received clearance from the FDA to move forward with phase 3 clinical trials for its COVID-19-influenza combination (CIC) and standalone influenza vaccines. The FDA lifted a clinical hold that ...

Good morning and welcome to Novavax' Third Quarter 2024 Financial Results and Operational Highlights Conference Call. All participants will be in listen-only mode. [Operator Instructions] After ...

Wall Street's main indexes fell on Tuesday as investors booked profits following post-election gains over the past few days, ...

Novavax shares fell after the company dropped its full-year revenue guidance with its third-quarter results. The company has cut its guidance multiple times this year, and the new range is below the ...